A Study To Evaluate The Effect Of WELLBUTRIN XL On Intraocular Pressure

Completed · Phase 1 · Has a placebo group

Conditions studied: Depressive Disorder

In brief

This study will be conducted in healthy volunteers to investigate the effect on intraocular pressure of 2 weeks of treatment with 300mg WELLBUTRIN XL/day.

Key facts

Study ID: NCT00439868
Run by: GlaxoSmithKline
People needed: 33
Starts: 2007-02-16
Expected to finish: 2007-06-08
Last updated by the study team: 2017-08-10

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

Healthy males or females.
Non-smokers
Agree to remain in the clinic for the time defined in the protocol.
Normal ECG.

You may not qualify if…

Any serious medical disorder or condition.
Any history of an endocrine disorder.
Any clinically significant laboratory abnormality.
History of psychiatric illness.
Any history of suicidal attempts or behavior.
Risk factors for precipitation of angle closure glaucoma or elevated IOP.
Inability to refrain from use of contact lenses during the study days, if correction is required.
Self-administered Beck Depression Inventory II scale total score greater than 9, and a suicide question score of greater than zero.
Current or past history of seizure disorder or brain injury (traumatic or disease-related); or any condition which, in the opinion of the investigator, predisposes to seizure - Women having a positive serum HCG pregnancy test at screening, a positive urine pregnancy test before admission to the Unit during the in-house periods, who are not willing to use acceptable methods of contraception or who are lactating or planning to become pregnant within the three months following the screening visit.

Where it is running

GSK Investigational Site — Gainesville, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.